Lupin Limited · NSE:LUPIN
Lupin — Q1 FY26 Earnings Presentation
20 slides from Lupin's earnings presentation, Aug 6, 2025
Slide 1: Exchange filing cover letter for Q1 FY26 investor presentation
August 06, 2025 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Investor Presentation - Q1 FY26 Results Dea
Slide 2: Investor Presentation Q1 FY26
Investor Presentation Q1 FY26 August 06, 2025
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q1 FY26 Performance
Q1 FY26 Performance
Slide 5: Q1 FY26 - Key Growth Metrics
Q1 FY26 - Key Growth Metrics Continued Strong Operating Performance Key Metrics Business Performance Values in INR unless indicated otherwise 61,638 mn Sales India APAC 12% YoY 20,894 mn | 8% YoY 3,158 mn | 3% YoY LATAM 1,738 mn | 17% YoY 16,414 mn EBITDA1 26.6% North America 28% YoY Margin 25,155 m
Slide 6: Q1 FY26 - Key Developments
Q1 FY26 - Key Developments Consistent improvement in margins Financials Key Launches / Approvals Sales* and EBITDA margin Trajectory Launched Rivaroxaban Tolvaptan tabs US FDA with sole Tabs 10/15/20mg (Jynarque®) approval 70,000 FTF 61,638 29.0% (Xarelto®) 60,000 55,143 54,970 56,186 55,622 27.0% B
Slide 7: Q1 FY26: Financial Snapshot
Q1 FY26: Financial Snapshot Sales Mix Key Financials INR mn Revenue (In INR mn and %) India, United Q1 FY26 Q1 FY25 Q4 FY25 20,894 States, 34% 24,0414 39% Sales 61,638 55,143 55,622 API, 2,431 4% EBITDA1 16,414 12,864 12,921 Other Emerging Other Developed 12,191 8,013 7,725 Markets3, Net Income2 Mar
Slide 8: India: Focus on market growth
India: Focus on market growth Brief Overview India business grew 7.8% YoY Continued Brief Overview momentum led by Leveraging Chronic Leadership investments in complex Gx, & 505(b)(2) India Sales (INR mn) #3 #2 #3 Rank Rank Rank 19,381 20,096 19,305 20,894 Respiratory2 Diabetes Care2 Cardiac2 17,113
Slide 9: India: Amplifying our Core
India: Amplifying our Core IRF business is poised to outperform IPM by 1.2-1.3x with key drivers in Enabling end to end healthcare ecosystem and access for the patient place Enhancing penetration and reach CHC Portfolio catering to GI, VMS, • Maximizing Chronic focus with ~70% share by FY30 Cough/co
Slide 10: United States: Continued momentum on Key Launches
United States: Continued momentum on Key Launches Leadership: ~4.5% Gx TRx volume Continued momentum led by Brief Overview Consistent Sales trajectory3 Brief Overview share in U.S.1 investments in complex Gx, & 505(b)(2) Sales in US$ Mn 22% YoY 13% QoQ • Plans to file 15+ Products in FY26 (2/3rd in
Slide 11: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and biosimilars Achieve Best-in-Class Quality Substantial Capabilities to become CGx powerhouse Recent Track Record Successful outcomes in last 12 months • Inhalation: Global presence with end-to-end capabilities of MDIs, DPIs, Soft-Mist I
Slide 12: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend R&D (INR mn) Capex (INR mn) Net Debt to Equity 6,000 5,346 15.0%2,500 15.0% 4,844 13.0% 2,086 13.0% 5,000 4,481 0.10 4,344 2,000 11.0% 11.0% 4,000 3,500 1,449 1,426 9.0% 1,500 9.0% 0.05 9.6% 1,241 3,000 7.0% 1,117 7.0% 0.02 8.2% 7.7% 7.9% 0.01 6.3% 5.0% 1,000 5
Slide 13: P&L Highlights Q1 FY26
P&L Highlights Q1 FY26 Particulars Q1’FY26 % of Sales Q1’FY25 % of Sales YoY Growth Q4’FY25 % of Sales QoQ Growth Net Sales 61,638 100.0% 55,143 100.0% 11.8% 55,622 100.0% 10.8% Other operating 1,045 1.7% 860 1.6% 21.6% 1,049 1.9% -0.4% income Total revenue 62,683 101.7% 56,003 101.6% 11.9% 57,671 1
Slide 14: Lupin at a Glance
ta Glance Lup if s =\ i =a =, ~ ae \ ®
Slide 15: Lupin Today
Lupin Today Global Presence Local Leadership Geographically Diverse Growing Sustainability Largest In the US (by India United States 3rd 75,773 79,975 14th $2.7 Bn prescriptions2) 34% 36% India Pharma Market Rank (by 8th Top 10% sales3) Largest Generic Annual sales Largest Australia Gx (by Company i
Slide 16: Catalyzing Treatments that serve Patients around the world
Catalyzing Treatments that serve Patients around the world United States Other Developed India Other Emerging API Markets Markets Substantial scale Driving operating Global reach and scale achieving reliability of Evolving portfolio and Delivering above- leverage in Portfolio, positions us as a supp
Slide 17: Lupin's ESG Update
Lupin’s ESG Update Paving a sustainable future for Planet, People and Patients ESG Goal Status FY 2025 Key Highlights Climate 38% GHG Reduction by Change1 23% GHG Reduction 2030 Water 50% Recycling by 2030 44% Recycling Biodiversity 6 Sites Completed Leadership rating in 100% Indian Sites 100% Globa
Slide 18: Lupin's ESG Update
Lupin’s ESG Update Our Purpose ESG Ratings Update We Catalyze treatments that transform hope into healing Sustainability Ratings Our ESG Framework Paving a Sustainable future for Planet, People & Patients 76/100 in 2024 S&P 26.3 Medium Risk in 2025. Global ESG Rating (17/100 2nd Consecutive year in
Slide 19: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Lupin placed among the Top 10% of companies in our industry based on S&P Global CSA score for 2024. Earns a spot in the esteemed S&P Global Sustainability Yearbook again • Lupin Research Park facility (Pune) awarded the LEED Platinum certification – the first pharmaceu
Slide 20: Thank You
Thank You lupin.com youtube.com/c/LupinGlobal x.com/LupinGlobal Registered Address facebook.com/LupinWorld/ 3rd Floor, Kalpataru Inspire, Off Western Express Phone: +91 22664 02323 linkedIn.com/company/lupin Highway, Santacruz (East), Mumbai - 400055, India Fax: +91 22664 02051